Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangsu Nanfang Medical Co (603880) Fair Value & Analysis

Healthcare · CN · Market cap 2.2B CNY

Price¥7.49
Fair Value¥1.89
Upside-74.8%
Quality95/100
Evidence: Medium Range ¥1.25 – ¥2.82

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Jiangsu Nanfang Medical Co (603880) currently trades at ¥7.49, while our model-based Fair Value estimate is ¥1.89 — implying the stock looks roughly 74.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal, medical proof fabrics, adhesive tapes and bandages, sports protection, first-aid kits, and care products in China and internationally. It offers medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesive, masks, and nitrile gloves, as well as customized products. The company was founded in 1990 and is headquartered in Changzhou, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Jiangsu Nanfang Medical Co (603880) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.89 versus a price of ¥7.49 — about −75% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 603880?
Our 21-model fair value for Jiangsu Nanfang Medical Co is ¥1.89 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥7.49.
What is the quality score of 603880?
Jiangsu Nanfang Medical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.